ArticleHaematologica2026
Age-related differences in donor selection priorities for allogeneic hematopoietic transplantation.
Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- [Impact of recipient age on outcomes of allogeneic hematopoietic stem cell transplantation: an analysis from the Chinese Bone Marrow Transplant Registry Group (CBMTRG)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Defying age: myth or reality?Haematologica · 2026Article
- Donor-recipient age difference, not donor age alone, predicts outcomes in allogeneic hematopoietic stem cell transplantation for aplastic anemia.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patient age might influence donor selection priorities in allogeneic hematopoietic stem cell transplantation (allo-HCT), due to the differences in donor age, organ function, and resistance to graft-versus-host disease between younger and older patients. We compared the transplant outcomes between patients aged <50 years and those aged ≥50 years who received transplants from human leukocyte antigen (HLA)-matched related donors (M-RD, N=4,106), HLA one-antigen-mismatched related donors (1MM-RD, N=592), HLA two or three-antigen-mismatched related donors (23MM-RD, N=882), HLA-matched unrelated donors (M-UD, N=3,927), HLA one-locus-mismatched unrelated donors (1MM-UD, N=2,474), or unrelated cord blood units (U-CB, N=5,867). To assess the impact of donor age, the M-UD and 1MM-UD groups were further subclassified into younger (M-UD-Y, 1MM-UD-Y: donor age <50 years) and older (M-UD-O, 1MM-UD-O: donor age ≥50 years) donor subgroups. Among patients aged ≥50 years, overall survival in the M-UD-Y group was significantly superior to that in the M-RD group (hazard ratio=0.87, P=0.0039), whereas the M-UD-O group showed no advantage (hazard ratio=1.08, P=0.48). In this age group, 1MM-RD, 23MM-RD, and U-CB were associated with significantly inferior overall survival, while neither 1MM-UD-Y nor 1MM-UD-O was. NRM was significantly lower in the M-UD-Y group than in the M-UD-O group among patients aged ≥50 years, without increasing relapse risk. For patients aged <50 years, overall survival in the M-UD-Y and M-UD-O groups was comparable to that in the M-RD group, but 23MM-RD, 1MM-UD-Y, and U-CB were associated with inferior overall survival. Therefore, donor selection priorities in allo-HCT might differ according to recipient age. A younger M-UD might be preferred for patients aged ≥50 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.